Xilio Therapeutics XLO
NASDAQ XLO
$7.57 -0.46 (-5.73%)
At close: Oct 23, 2026 · 4:00 PM EDT

Xilio Therapeutics (XLO) Gains from Sales and Divestitures (2023 - 2024)

Updated

Xilio Therapeutics (XLO) recorded Gains from Sales and Divestitures of -$5,000 in Q4 2024.

Analysis

Xilio Therapeutics (XLO) Gains from Sales and Divestitures (2023 - 2024) Analysis & Trends

For FY2024, Xilio Therapeutics reported Gains from Sales and Divestitures of -$3,000.

  • Across earlier years, Gains from Sales and Divestitures came in at -$3,000 in FY2023, -$1,000 in FY2022 and -$19,000 in FY2021.
  • The Q4 2024 figure is the highest quarterly Gains from Sales and Divestitures since Q3 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 Xilio Therapeutics 146.89 Mn -380.77 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -5,000.00
Sep 30, 2023 -1,000.00
API Access

Xilio Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=XLO&period=max&api_key=YOUR_API_KEY